The research covers results obtained using a variety of PET tracers to diagnose diseases, including the combination of LMI's florbetaben F-18 injection (Neuraceq) and PI-2620 to detect tau pathology. Other highlights include results from a multicenter investigation on the benefits of using PI-2620 to detect progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS).

"PI-2620's ability to also detect 4R tauopathies, such as PSP and CBS, allows us to pursue the development of PI-2620 not only for Alzheimer's disease, but also for additional neurodegenerative diseases, where previous tau tracers showed limitations," noted Dr. Andrew Stephens, PhD, chief medical officer of LMI, in a press statement.